- Details
- Nicholas Zorko discusses the promising role of natural killer (NK) cells in prostate cancer, described his team’s study published in Prostate Cancer and Prostatic Diseases. The research reveals that increased NK cell infiltration in prostate tumors correlates with improved patient outcomes, suggesting NK cells as a potential next frontier in cellular therapies for prostate cancer. The study utiliz...
|
- Details
- Stacy Loeb discusses her study on digital health information trust among Black prostate cancer patients, published in the Journal of Urology. Dr. Loeb's research reveals a stark lack of racial and ethnic diversity in online prostate cancer content, which significantly impacts trust among Black patients. This study, underpinned by analysis of social network use and content representation, involves...
|
- Details
- Anqi Wang unveils findings from her study published in Nature Genetics. Dr. Wang's research marks a significant advance in understanding the genetic landscape of prostate cancer, identifying a total of 451 independent risk loci, including 187 novel variants, through an expanded multi-ancestry meta-analysis. This study not only enlarges the scope of known genetic risk factors but also emphasizes th...
|
- Details
- Antonina Mitrofanova delves into her team's research published in Nature Communications. The study uncovers the NME2 and MYC programs as pivotal markers of enzalutamide resistance in castration-resistant prostate cancer (CRPC). Dr. Mitrofanova's team embarked on this journey following observations that patients with elevated MYC levels showed increased resistance to androgen receptor signal inhibi...
|
- Details
- Tanya Stoyanova discusses research on Trop2's role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study reveals Trop2 as a high-potential therapeutic target due to its overexpression in various epithelial cancers, including prostate cancer, where it's linked to aggressive behavior. Their work, validated in a large patient cohort...
|
- Details
- Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients' prostates and lymph nodes, the study uncovers significant genomic heterogen...
|
- Details
- Massimo (Max) Loda discusses his team’s research on the role of the microenvironment in prostate cancer progression, published in Nature Communications. The study focuses on the stroma's significance in prostate carcinogenesis. Utilizing mouse models and human tumors, they performed single-cell RNA sequencing to analyze stromal cells in different stages of prostate cancer. The research revealed di...
|
- Details
- Andrea Miyahira hosts Andrew Goldstein to discuss his group's research on prostate cancer, published in Nature Cell Biology. Dr. Goldstein, along with his team, including grad students Jenna Giafaglione and Preston Crowell, explores the metabolic processes influencing prostate cancer's response to anti-androgen treatment. Their study reveals that basal and luminal cells in the prostate have distin...
|
- Details
- Andrea Miyahira hosts Johann De Bono to discuss his group's paper on reversing prostate cancer therapy resistance by targeting myeloid chemotaxis. Dr. De Bono, with contributions from his team, including Christina Guo and Adam Sharp, explores the role of inflammation in prostate cancer. The study focuses on how stressed cancer cells attract inflammatory cells, which can then support tumor growth a...
|
- Details
- Andrea Miyahira hosts Ping Mu to discuss his group's research on prostate cancer resistance to anti-androgens. Dr. Mu's study, published in Oncogene, focuses on the gene UBE2J1, identified as a key E2 ubiquitin-conjugating enzyme regulating Androgen Receptor (AR) degradation. He explains that despite advancements in anti-androgen therapies like enzalutamide, resistance remains a significant challe...
|
